Article

Duke Macular Translocation Study group reports recurrence rates

There is a low rate of recurrent choroidal neovascularization (CNV) over 2 years in eyes that undergo macular translocation surgery with 360-degree peripheral retinectomy (MT-360) for exudative age-related macular degeneration, said Claxton A Baer, MD.

May 4

- Fort Lauderdale, FL - There is a low rate of recurrent choroidal neovascularization (CNV) over 2 years in eyes that undergo macular translocation surgery with 360-degree peripheral retinectomy (MT-360) for exudative age-related macular degeneration, said Claxton A Baer, MD.

He presented data from a series of 64 eyes of 64 participants in the Duke Macular Translocation study. That prospective, noncomparative trial enrolled second eyes of patients with neovascular age-related macular degeneration who were ineligible for or failed nonsurgical treatment.

Among 56 eyes seen at 2 years, 14 (25%) had developed recurrent CNV. No eyes developed geographic atrophy. Most cases of recurrence occurred within the first 9 months after surgery, only 2 patients developed recurrence after 1 year, and there were no new recurrences between 18 and 24 months. Thirteen of the 14 recurrences occurred from the old CNV bed and all crossed the margin of the old CNV bed.

Median visual acuity for the 14 eyes with recurrent CNV was 20/200 versus 20/80 for those without recurrence.

"We recommend close surveillance for recurrence in the first year after this surgery with special attention to the foveal side of the CNV bed as early recognition and new methods of treatment for CNV may prevent vision loss in this subgroup and improve overall outcomes," Dr. Baer said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.